Lipfendra (Enlicitide): First Oral PCSK9 Inhibitor Approved by the US FDA

Why in News?

The U.S. Food and Drug Administration (FDA) approved Lipfendra (enlicitide) on 16 July 2026 for lowering low-density lipoprotein cholesterol (LDL-C) in adults. It is the world’s first FDA-approved oral PCSK9 inhibitor, offering a once-daily 20 mg tablet as an alternative to injectable cholesterol-lowering therapies.

What is Lipfendra?

Lipfendra is approved as an adjunct to diet and exercise for adults with hypercholesterolaemia, including those with heterozygous familial hypercholesterolaemia (HeFH), an inherited condition that causes abnormally high LDL cholesterol levels.

Unlike existing injectable PCSK9 inhibitors, Lipfendra is taken orally once a day, making cholesterol management more convenient for patients requiring long-term treatment.

How Do PCSK9 Inhibitors Work?

PCSK9 inhibitors target the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein, which regulates the number of LDL receptors present on liver cells. By blocking PCSK9, more LDL receptors remain available to remove LDL cholesterol (“bad cholesterol”) from the bloodstream, thereby significantly lowering cholesterol levels and reducing cardiovascular risk.

Clinical Trial Results

The FDA approval was based on two large Phase 3 clinical trials—CORALreef Lipids and CORALreef HeFH—involving 3,207 adult participants.

The CORALreef Lipids trial showed that Lipfendra reduced LDL cholesterol by an average of 56% compared to placebo after 24 weeks. A post-hoc analysis reported an even greater reduction of 60% after excluding certain baseline values.

The safety profile was generally favourable. In the CORALreef HeFH trial, diarrhoea occurred in 7% of patients receiving Lipfendra compared to 2% in the placebo group, while dizziness was reported in 9% and 4%, respectively.

Significance

The approval of Lipfendra marks a major advancement in cardiovascular medicine by introducing the first oral PCSK9 inhibitor. It expands treatment options for patients who require intensive LDL cholesterol reduction but prefer an oral medicine over injectable therapies, potentially improving long-term treatment adherence.

Important Facts for Exams

• Lipfendra (enlicitide) is the first FDA-approved oral PCSK9 inhibitor.
• It is administered as a once-daily 20 mg tablet.
• LDL cholesterol is commonly known as “bad cholesterol.”
• Heterozygous Familial Hypercholesterolaemia (HeFH) is an inherited disorder causing high LDL cholesterol.
• The approval was based on the CORALreef Lipids and CORALreef HeFH Phase 3 trials involving 3,207 participants.
• Phase 3 clinical trials evaluate the efficacy and safety of a drug before regulatory approval.
• Ezetimibe is another cholesterol-lowering medicine that works by reducing intestinal cholesterol absorption.